Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Neurogene (NGNE) Operating Income (2018 - 2025)

Historic Operating Income for Neurogene (NGNE) over the last 5 years, with Q3 2025 value amounting to -$23.8 million.

  • Neurogene's Operating Income fell 729.49% to -$23.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$97.3 million, marking a year-over-year decrease of 2833.33%. This contributed to the annual value of -$82.6 million for FY2024, which is 4861.56% down from last year.
  • Per Neurogene's latest filing, its Operating Income stood at -$23.8 million for Q3 2025, which was down 729.49% from -$26.1 million recorded in Q2 2025.
  • Neurogene's 5-year Operating Income high stood at -$12.6 million for Q2 2023, and its period low was -$26.1 million during Q2 2025.
  • Its 3-year average for Operating Income is -$19.5 million, with a median of -$20.1 million in 2024.
  • Its Operating Income has fluctuated over the past 5 years, first crashed by 5984.44% in 2024, then tumbled by 729.49% in 2025.
  • Neurogene's Operating Income (Quarter) stood at -$14.7 million in 2023, then plummeted by 46.01% to -$21.5 million in 2024, then fell by 10.63% to -$23.8 million in 2025.
  • Its Operating Income was -$23.8 million in Q3 2025, compared to -$26.1 million in Q2 2025 and -$25.9 million in Q1 2025.